tetano
Editor, Senior Moderator
Clin Exp Vaccine Res
. 2022 Jan;11(1):116-120.
doi: 10.7774/cevr.2022.11.1.116. Epub 2022 Jan 31.
Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults
Juandy Jo[SUP] 1 2 [/SUP], Astia Sanjaya[SUP] 1 [/SUP], Reinhard Pinontoan[SUP] 1 [/SUP], Maroloan Aruan[SUP] 3 [/SUP], Rury Mega Wahyuni[SUP] 2 [/SUP], Venansi Viktaria[SUP] 2 [/SUP]
Affiliations
Abstract
The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.
Keywords: Anti-SARS-CoV-2 RBD antibody; COVID-19; CoronaVac vaccine.
. 2022 Jan;11(1):116-120.
doi: 10.7774/cevr.2022.11.1.116. Epub 2022 Jan 31.
Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults
Juandy Jo[SUP] 1 2 [/SUP], Astia Sanjaya[SUP] 1 [/SUP], Reinhard Pinontoan[SUP] 1 [/SUP], Maroloan Aruan[SUP] 3 [/SUP], Rury Mega Wahyuni[SUP] 2 [/SUP], Venansi Viktaria[SUP] 2 [/SUP]
Affiliations
- PMID: 35223672
- PMCID: PMC8844676
- DOI: 10.7774/cevr.2022.11.1.116
Abstract
The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.
Keywords: Anti-SARS-CoV-2 RBD antibody; COVID-19; CoronaVac vaccine.